NCT05215548 2025-02-19Primary Tumor Resection With EGFR TKI for Stage IV NSCLCNational Taiwan University HospitalPhase 2 Active not recruiting100 enrolled
NCT04201756 2022-12-23Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaShanghai Pulmonary Hospital, Shanghai, ChinaPhase 2 Completed47 enrolled